Leigh Baldwin & Co’s iShares Biotechnology ETF IBB Stock Holding History

Leigh Baldwin & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+1,176	New	+$202K	0.12%	167

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Leigh Baldwin & Co's IBB Position: Q2 2026 in Review

Leigh Baldwin & Co opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,176 shares worth $224K. The stake represents 0.12% of the portfolio and ranks #167 among its holdings.

954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Leigh Baldwin & Co held 1,176 shares of iShares Biotechnology ETF worth $224K as of Q2 2026.
iShares Biotechnology ETF was a new Leigh Baldwin & Co position in Q2 2026.
iShares Biotechnology ETF made up 0.12% of Leigh Baldwin & Co's portfolio in Q2 2026, its #167 holding.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Leigh Baldwin & Co's 13F filing for Q2 2026, filed 13 Aug 2026.